NCT03536598

Study to Evaluate the Safety and Efficacy of CJ-30060 in Hypertensive Patients With Hyperlipidemia

A Double-blind, Randomized, Multi-center Phase III Clinical Trial to Evaluate the Safety and Efficacy of CJ-30060 Compared With Amlodipine/Valsartan Combination Therapy and Valsartan/Rosuvastatin Combination Therapy in Hypertensive Patients With Hyperlipidemia

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 203 (actual)
• Sponsor: HK inno.N Corporation · Industry
• Sex: All
• Age: 19 Years – 74 Years
• Healthy volunteers: Not accepted

Summary

To evaluate the safety and efficacy of CJ-30060 compared with amlodipine/valsartan combination therapy and valsartan/rosuvastatin combination therapy in hypertensive patients with hyperlipidemia

Conditions

• Hypertension With Hyperlipidemia

Interventions

Type	Name	Description
DRUG	Amlodipine 10 mg + Valsartan 160 mg + Rosuvastatin 20 mg
DRUG	Amlodipine 10 mg + Valsartan 160 mg
DRUG	Valsartan 160 mg + Rosuvastatin 20 mg

Timeline

• Start date: 2016-10-14
• Primary completion: 2017-09-04
• Completion: 2017-09-04
• First posted: 2018-05-24
• Last updated: 2018-05-30